CHEK2 and colorectal carcinoma: To determine if LV co-treatment affected the activation of the ATR/Chk1 or ATM/Chk2 pathways, we also analyzed lysates from CRC cells with FP + LV co-treatment for all three FPs tested (CF10, 5-FU, TFT).